| Inclusion Criteria: | 1) Adult patients with a known deleterious mutation in any of the genes associated with Hereditary Breast and Ovarian Cancer (BRCA1 and BRCA2 genes), Lynch syndrome (MLH1, MSH2, MSH6, and PMS2 genes), FAP (APC gene), MEN1 (MEN1 gene), MEN2 (RET gene), and VHL (VHL gene) are eligible for the study.
2) Additionally, obligate carriers will also be included in the study. Obligate carriers are individuals who have not undergone genetic testing, but are known to have a deleterious mutation because they have a clinical diagnosis of the condition and a relative with a known deleterious mutation. For example, a mother who has a clinical diagnosis of FAP who has a son with a deleterious gene mutation associated with FAP, is an obligate carrier of the same gene mutation as her son.
3) Participants must be age 18 or older, able to read and write English, and able to provide written informed consent.
4) Participants must have completed at least one visit with a genetic counselor at M. D. Anderson Cancer Center.
5) At M.D. Anderson, eligible participants must have given prior consent to be contacted about research studies. If they have not previously been asked about being recontacted for future research studies, they will be contacted by their genetic counselor and asked if they would be willing to participate in this particular study before they are sent a questionnaire. |